

University of Groningen

## DNA nanoparticles as ocular drug delivery platform

de Vries, Jan Willem

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2015

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

de Vries, J. W. (2015). DNA nanoparticles as ocular drug delivery platform [Groningen]: University of Groningen

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# **DNA Nanoparticles as Ocular Drug Delivery Platform**

Jan Willem de Vries

# DNA Nanoparticles as Ocular Drug Delivery Platform

Jan Willem de Vries  
PhD thesis  
University of Groningen

September 2015

Zernike Institute PhD thesis series 2015-12

ISSN: 1570-1530  
ISBN (print): 978-90-367-8015-5  
ISBN (electronic): 978-90-367-8014-8

The research described in this thesis was carried out in the Polymer Chemistry and Bioengineering group at the Zernike Institute for Advanced Materials, University of Groningen, The Netherlands. This work was funded by The Netherlands Organization for Scientific Research (NWO) and the European Research Council



Cover design: Annika Geurtsen  
Printed by: Ipskamp Drukkers B.V. Enschede



rijksuniversiteit  
 groningen

# **DNA Nanoparticles as Ocular Drug Delivery Platform**

## **Proefschrift**

ter verkrijging van de graad van doctor aan de  
 Rijksuniversiteit Groningen  
 op gezag van de  
 rector magnificus prof. dr. E. Sterken  
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op  
 vrijdag 18 september 2015 om 16.15 uur

door

**Jan Willem de Vries**

geboren op 26 mei 1987  
 te Bolsward

**Promotor**

Prof. dr. A. Herrmann

**Beoordelingscommissie**

Prof. dr. A.S.S. Dömling

Prof. dr. G. Molema

Prof. dr. S. Otto

*Few are those who see with their own eyes  
and feel with their own hearts.*

Albert Einstein



# Contents

<b>1. Drug delivery systems based on nucleic acid nanostructures .....</b>	<b>1</b>
1.1 Introduction .....	1
1.2 Delivery with pristine DNA scaffolds .....	5
1.2.1 DNA tetrahedral .....	5
1.2.2 Branched DNA nanostructures and polyiods .....	10
1.2.3 DNA icosahedra .....	12
1.2.4 DNA origami .....	14
1.3 Delivery with scaffolds consisting of nucleic acids combined with other materials .....	22
1.3.1 DNA nanoparticles with an inorganic core .....	22
1.3.2 Amphiphilic DNA block copolymers .....	32
1.4 Conclusion .....	39
1.5 Thesis motivation and overview .....	44
1.6 References .....	46
<b>2. Synthesis and characterization of DNA block copolymers revisited .....</b>	<b>55</b>
2.1 Introduction .....	55
2.2 Results and discussion .....	60
2.2.1 DBC synthesis and characterization .....	60
2.2.2 Investigation of polymer influence on the melting temperature .....	66
2.3 Conclusion .....	69
2.4 Experimental .....	69
2.4.1 Materials .....	69
2.4.2 Synthesis of poly(propylene oxide) amidite .....	70
2.4.3 DNA block copolymer synthesis and purification .....	70
2.4.4 Characterization of DBCs .....	71
2.4.4 Melting temperature determination .....	72
2.5 Acknowledgement .....	74
2.6 References .....	74



<b>3. Ocular adhesion of lipid-DNA nanoparticles .....</b>	<b>77</b>
3.1 Introduction .....	77
3.2 Results and discussion .....	79
3.2.1 Nanoparticle design and characteristics .....	79
3.2.2 Determination of best NP binding <i>in-vitro</i> and <i>in-vivo</i> .....	80
3.2.3 Time dependent adherence of U4-12 .....	83
3.3 Conclusion .....	85
3.4 Experimental.....	86
3.4.1 Materials.....	86
3.4.2 Synthesis and characterization of amphiphilic oligonucleotides	87
3.4.3 Preparation of functionalized NPs.....	90
3.4.5 Critical micelle concentration determination .....	90
3.4.4 Determination of adherence to porcine eye.....	92
3.4.5 Selection of best adhering NP and evaluation of adherence time on the cornea .....	92
3.5 References .....	93
<b>4. Preclinical evaluation of DNA nanoparticles for ophthalmic drug delivery.....</b>	<b>95</b>
4.1 Introduction.....	95
4.2 Results and discussion .....	98
4.2.1 Delivery of antibiotic-loaded NPs to the cornea .....	98
4.2.2 Adherence of antibiotic loaded NPs to the human cornea .....	100
4.2.3 Antimicrobial activity of loaded NPs in medium .....	102
4.2.4 Activity and Efficacy of antibiotic-loaded NPs.....	103
4.3 Conclusion .....	106
4.4 Experimental.....	107
4.4.1 Preparation of functionalized NPs.....	107
4.4.2 Adherence of antibiotic-loaded NPs to living rat eyes .....	107
4.4.3 Human cornea experiments .....	108
4.4.4 Minimum inhibitory concentration tests .....	108
4.4.5 Evaluation of antibiotic activity on porcine cornea.....	109
4.4.6 Fluorescent labeling of aminoglycoside antibiotics .....	109
4.4.7 Nanoparticle (NP) imaging by transmission electron microscopy (TEM) .....	111

4.5 Acknowledgement .....	112
4.6 References.....	113
<b>5. Stability and toxicity of lipid DNA nanoparticles .....</b>	<b>115</b>
5.1 Introduction .....	115
5.2 Results and discussion.....	118
5.2.1 Evaluation of toxicity profile in cell cultures .....	118
5.2.2 <i>In-vivo</i> toxicity study .....	119
5.2.3 Stability determination by gel electrophoresis.....	121
5.2.4 Evaluation of NP stability by liquid chromatography.....	122
5.3 Conclusion .....	128
5.4 Experimental .....	129
5.4.1 Materials .....	129
5.4.2 Preparation of functionalized NPs .....	129
5.4.3 Toxicity studies on ocular cell lines .....	130
5.4.4 <i>In-vivo</i> toxicity evaluation .....	131
5.4.5 Stability assessment of pristine and antibiotic loaded U4-12 NPs .....	132
5.5 Acknowledgement .....	132
5.6 References.....	132
<b>Summary.....</b>	<b>135</b>
<b>Samenvatting .....</b>	<b>139</b>
<b>Acknowledgement .....</b>	<b>143</b>
<b>Curriculum vitae .....</b>	<b>147</b>

